Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma

Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma

(2009) D Yoshikawa et al.   BRITISH JOURNAL OF CANCER

Establishment of six new human biliary tract carcinoma cell lines and identification of MAGEH1 as a candidate biomarker for predicting the efficacy of gemcitabine treatment

(2009) Hidenori Ojima et al.   CANCER SCIENCE

Novel Therapeutic Inhibitors of the c-Met Signaling Pathway in Cancer

(2009) J. P. Eder et al.   CLINICAL CANCER RESEARCH

Resistance to EGF-R (erbB-1) and VEGF-R modulating agents

(2009) Wolfram C.M. Dempke et al.   EUROPEAN JOURNAL OF CANCER

Cholangiocarcinoma

(2009) Patrick Yachimski et al.   JOURNAL OF CLINICAL GASTROENTEROLOGY

Prognostic significance of c-Met expression in glioblastomas

(2008) Doo-Sik Kong et al.   CANCER

The Met tyrosine kinase receptor in development and cancer

(2008) Alessandra Gentile et al.   CANCER AND METASTASIS REVIEWS

Single-Agent and Combination Therapeutic Strategies to Inhibit Hepatocyte Growth Factor/MET Signaling in Cancer

(2008) L. Toschi et al.   CLINICAL CANCER RESEARCH

Cholangiocarcinoma: Advances in pathogenesis, diagnosis, and treatment

(2008) Boris Blechacz et al.   HEPATOLOGY

Evidence-Based Approach to Cholangiocarcinoma: A Systematic Review of the Current Literature

(2008) Murad Aljiffry et al.   JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS

Transcription-Dependent Epidermal Growth Factor Receptor Activation by Hepatocyte Growth Factor

(2008) T. E. Reznik et al.   MOLECULAR CANCER RESEARCH

Systemic Therapy for Biliary Tract Cancers

(2008) A. F. Hezel et al.   ONCOLOGIST

Signaling networks assembled by oncogenic EGFR and c-Met

(2008) A. Guo et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

c-Met targeted therapy of cholangiocarcinoma

(2008) Matei P Socoteanu et al.   WORLD JOURNAL OF GASTROENTEROLOGY